These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2064457)

  • 41. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
    Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
    Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
    Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
    Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anemia management in patients with chronic conditions that affect erythropoiesis. Case study of the anemic patients.
    Deziel SM
    Nephrol Nurs J; 2002 Dec; 29(6):582-5. PubMed ID: 12596607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
    Cotton SL; Holechek MJ
    ANNA J; 1989 Dec; 16(7):463-8. PubMed ID: 2604448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
    Sapojnikov M; Veksler A; Yagil Y; Kogan J; Turkot S; Boris G; Oren S
    Ren Fail; 2005; 27(2):199-203. PubMed ID: 15807186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive function in dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1997 Jun; 24(3):359-65; quiz 366. PubMed ID: 9238909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Case study of the anemic patient: epoetin alfa--focus on erythrokinetics.
    Chmielewski CM
    ANNA J; 1995 Aug; 22(4):420-3. PubMed ID: 7654091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nephrology nursing care plan and patient education plan for the patient receiving Epogen.
    Prowant BF; Gallagher NM; Binkley LS; Latham D; Nichols E
    ANNA J; 1991 Apr; 18(2):188-93. PubMed ID: 2025050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing an epoetin alfa medication protocol to improve patient care and foster collaboration.
    Shanahan M; Walton S
    ANNA J; 1995 Oct; 22(5):471-6. PubMed ID: 7487190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Documentation of anemia management interventions. Case study of the anemic patient.
    Kammerer J
    Nephrol Nurs J; 2000 Aug; 27(4):399-402. PubMed ID: 11276631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the management of chronic renal failure: the use of epoetin alfa in clinical practice. Proceedings of a symposium. June 6, 1989, Nashville, TN.
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):1S-26S. PubMed ID: 2345707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.